Literature DB >> 18806295

Microplasmin: ex vivo characterization of its activity in porcine vitreous.

Marc D de Smet1, Christophe Valmaggia, Javier Zarranz-Ventura, Ben Willekens.   

Abstract

PURPOSE: Microplasmin is a recombinant protein limited to the enzymatic moiety of plasmin without any of its cringle domains. Its enzymatic activity is similar to that of plasmin enzyme. The present study characterizes in a porcine eye model the vitreolytic ability of microplasmin.
METHOD: Freshly harvested porcine eyes were used in these trials. Eyes were injected with escalating doses of microplasmin (62.5, 125, 250, 400 microg) for 1 hour or with 125 microg microplasmin with increasing time exposures (15, 30, 60, 120 minutes). Eyes were fixed by a very slow dehydration process to preserve the integrity of the vitreous retinal interface. They were examined by light microscopy to determine the degree of posterior vitreous detachment and by scanning electron microscopy (SEM) to study structural changes.
RESULTS: Effective separation of the posterior hyaloid appeared to be dose dependent. After 1 hour, the posterior pole was detached in 100% of porcine eyes exposed to 125 microg microplasmin and in the midperiphery to 250 microg microplasmin. Vitreous at the ora did not detach. At 120 minutes of exposure, midperipheral detachment was observed with 125 microg microplasmin. A smooth retinal surface was seen where the enzyme caused posterior vitreous detachment. There was also significant change to the integrity of the vitreous without any obvious structural alterations to the retina by histology or scanning electron microscopy.
CONCLUSIONS: Microplasmin caused vitreolysis and posterior vitreous separation in an ex vivo porcine eye model in an apparent dose- and time-dependent fashion. In this model system, the minimal effective dose appeared to be 125 microg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806295     DOI: 10.1167/iovs.08-2185

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  [Pharmacological vitreolysis].

Authors:  C Haritoglou; A Kampik
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

2.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

3.  Foveola nonpeeling internal limiting membrane surgery to prevent inner retinal damages in early stage 2 idiopathic macula hole.

Authors:  Tzyy-Chang Ho; Chung-May Yang; Jen-Shang Huang; Chang-Hao Yang; Muh-Shy Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-23       Impact factor: 3.117

4.  Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.

Authors:  Ricarda G Schumann; Julian Langer; Denise Compera; Katharina Luedtke; Markus M Schaumberger; Thomas Kreutzer; Wolfgang J Mayer; Armin Wolf; Siegfried G Priglinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-28       Impact factor: 3.117

Review 5.  Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Authors:  Yahiya Y Syed; Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 6.  Fibrinolytic Enzymes for Thrombolytic Therapy.

Authors:  Swaroop S Kumar; Abdulhameed Sabu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

8.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01

Review 9.  Retinal Changes Induced by Epiretinal Tangential Forces.

Authors:  Mario R Romano; Chiara Comune; Mariantonia Ferrara; Gilda Cennamo; Stefano De Cillà; Lisa Toto; Giovanni Cennamo
Journal:  J Ophthalmol       Date:  2015-09-03       Impact factor: 1.909

Review 10.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.